MaxCyte launches share issue to raise at least £10n

Writer, Stock Market Wire
Tuesday, February 5, 2019 - 07:34

Cell-based medicines company MaxCyte Group launched a share issue to raise at least £10.0m to fund an acceleration of its growth strategy.

New shares in the company would be issued at 170p each.

MaxCyte said the raising would support an expansion of its cell-therapy pipeline and the formation of clinical and commercial deals.

Related content

MaxCyte books annual loss owing to R&D, marketing spending

Cell-based medicines group MaxCyte booked a full-year loss after rising sales were more than offset by spending, including on R&D and marketing.

Net losses for...

Wed, 24/04/2019 - 07:52

MaxCyte launches new cell therapy technology platform

MaxCyte said it had launched a new technology platform for flow electroporation.

The technology was for complex cellular engineering, which the company said would solidify...

Mon, 08/04/2019 - 08:27

MaxCyte expands commercial relationship with Kit

MaxCyte said it had expanded its relationship with Kite, a Gilead company, by entering into a multi-drug clinical and commercial agreement.

Under the terms of...

Fri, 01/03/2019 - 08:32

MaxCyte expects annual earnings beat as revenue rises 19%

Cell-based medicines company MaxCyte said it expected to post annual operating earnings ahead of market expectations after it sales rose by almost a fifth.


Tue, 15/01/2019 - 07:52

MaxCyte to present technology to analysts next week

Cell-based medicines developer MaxCyte said it would hold a webinar for sell-side analysts on Tuesday to display its technology.

The presentation would demonstrate how its...

Fri, 16/11/2018 - 07:40